|
|
| |
|
HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE
This course requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.
Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
|
| |
|
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Elsevier Office of Continuing Medical Education (EOCME) and Elsevier. The EOCME is accredited by the ACCME to provide continuing medical education (CME) for physicians.
|
| |
|
CREDIT DESIGNATION STATEMENT
The EOCME designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
| |
|
DISCLOSURES
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of anyone who is in a position to control the content of an educational activity. All relevant financial relationships with any commercial interests and/or manufacturers must be disclosed to participants at the beginning of each activity. The faculty of this CME activity disclose the following:
|
Faculty Member
|
|
Manufacturer
|
|
Relationship
|
| Catalin Boiangiu, MD |
|
Nothing to disclose |
|
|
| David Morrow, MD |
|
Accumetrics, AstraZeneca, Bayer Healthcare, Beckman Coulter, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Eli Lilly & Co., Genentch, Inotek Pharmaceuticals, Integrated Therapeutics, Johnson & Johnson, Merck & Co., Merck/Schering-Plough, Nanosphere, Novartis, Nuvelo, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, sanofi-aventis U.S., Siemens Medical Solutions, Singulex, Schering-Plough |
|
Grants/Research Support |
| |
|
Beckman Coulter, Molecular Insight, sanofi-aventis U.S., Schering Plough Research Institute, Siemens Medical Solutions, Roche Diagnostics |
|
Consultant/Advisory Board |
| |
|
Beckman-Coulter, CV Therapeutics, Eli Lilly and Co., sanofi-aventis U.S. |
|
Honoraria |
| Geno J. Merli, MD, FACP |
|
Boehringer Ingelheim GmbH, Bristol-Myers Squibb, sanofi-aventis US |
|
Grants/Research Support |
| |
|
Bacchus Vascular, Inc., Bristol-Myers Squibb, sanofi-aventis US |
|
Consultant |
| |
|
sanofi-aventis US |
|
Speaker’s Bureau |
| Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP |
|
Bristol-Myers Squibb, Eisai, Ethicon, The Medicines Company, sanofi-aventis US |
|
Grants/Research Support |
| |
|
AstraZeneca, Bristol-Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, McNeil, The Medicines Company, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, sanofi-aventis US, Schering-Plough, TNS Healthcare, Vertex |
|
Consultant |
| |
|
Bristol-Myers Squibb, The Medicines Company, sanofi-aventis US |
|
Speaker’s Bureau |
| Activity Director |
|
|
|
|
| Paul Ruest, PhD |
|
Elsevier |
|
Nothing to disclose |
| Jennifer DiBenedetto, EdM |
|
EOCME |
|
Nothing to disclose |
|
| |
|
RESOLUTION OF CONFLICT OF INTEREST
The EOCME has implemented a process to resolve conflicts of interest for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public, the EOCME has resolved the conflict by conducting peer review.
|
| |
|
UNAPPROVED/OFF-LABEL USE DISCLOSURE
The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
2. Any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labeling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
|
| |
|
INTENDED AUDIENCE
This CME activity has been developed for emergency medicine physicians, cardiologists, internists, hospitalists, and other health care providers who treat patients in a hospital setting.
|
| |
|
PROGRAM GOALS
Based on the program educational material, participants should be able to understand and direct optimal antithrombotic therapeutic regimens when treating non–ST-elevation myocardial infarction (NSTEMI) patients. Completion of this activity should also be accompanied by an understanding of recent clinical trials that are directed towards addressing optimal NSTEMI treatment with either conservative or invasive methodology.
|
| |
|
EDUCATIONAL OBJECTIVES
After completing this educational activity and the post-test, participants should be able to:
- Select treatment options for patients who present with NSTEMI based on risk stratification
- Describe the rationale for selection of an optimal therapeutic regimen utilizing a conservative vs an invasive approach
- Relate current NSTEMI recommendations for treatment to specific patient profiles
- Discuss the impact of recent clinical trials on use of low-molecular-weight heparin (LMWH), anti-Xa agents, direct thrombin inhibitors, and glycoprotein (GP) IIb/IIIa inhibitors in selecting a therapeutic approach
- Evaluate current practice standards to determine accordance with guideline recommendations regarding the treatment of patients with non–ST-elevation (NSTE) acute coronary syndromes (ACS) who are undergoing percutaneous coronary intervention (PCI) or being treated medically
Release Date of Activity: April 2009
Expiration Date of Activity for AMA PRA Credit: March 31, 2011
Estimated Time to Complete This Activity: 2.0 hours
|
| |
|
FINANCIAL SUPPORT
This CME activity is supported by an educational grant from sanofi-aventis US.
|
| |
|
CME PLANNING COMMITTEE
Catalin Boiangiu, MD
David Morrow, MD
Geno J. Merli, MD, FACP
Deepak L. Bhatt, MD, FACC, FSCAI, FESC, FACP
Paul Ruest, PhD
Jennifer DiBenedetto, EdM
|
| |
|
CME INQUIRIES
For all CME certificate inquiries, please contact Sandy Bakos at s.bakos@elsevier.com.
|
| |
|
SPECIAL NEEDS
We encourage participation by all individuals. If you have any special needs, please contact Kelly Kramer at (908) 547-2182 or k.kramer@elsevier.com for assistance.
|